CVT/Astellas To Submit Regadenoson In Mid-2007, Following Successful Phase III Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
Selective adenosine receptor agonist could replace market leader Adenoscan as the myocardial perfusion imaging agent of choice, CVT says.
You may also be interested in...
FDA Clears Astellas’ Lexiscan For Market
Bigger sales force backs soon-to-launch imaging agent.
FDA Clears Astellas’ Lexiscan For Market
Bigger sales force backs soon-to-launch imaging agent.
CVT/Astellas Submit Next-Gen Cardiac Stress Agent Regadenoson
CV Therapeutics and Astellas Pharma submitted an NDA for their novel cardiac imaging stress agent regadenoson May 14, CVT told "The Pink Sheet" DAILY